SEC Form 4 · accession 0001214659-19-001486
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — President & CEO · Director
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2019 | M | 79 | $24.99 | A | 62,497 | D | |
| Common Stock | Feb 21, 2019 | M | 2 | $5.40 | A | 62,499 | D | |
| Common Stock | Feb 21, 2019 | M | 3,542 | $21.51 | A | 66,041 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $24.99 | Feb 21, 2019 | M | 79 | D | — | Jan 21, 2026 | Common Stock | 79 | 114,921 | D |
| Stock Option (Right to Buy)F1 | $5.40 | Feb 21, 2019 | M | 2 | D | — | Jan 25, 2027 | Common Stock | 2 | 109,998 | D |
| Stock Option (Right to Buy)F1 | $21.51 | Feb 21, 2019 | M | 3,542 | D | — | Feb 3, 2025 | Common Stock | 3,542 | 81,458 | D |
Explanation of responses
- F11/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.